Xin Zan

Xin Zan

Auto-generated profile, based on publicly available information

Xin Zan

Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Chemical Engineering Journal
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
FZFanjun Zhang
Fanjun Zhang
LLLinyu Long
Linyu Long
JLJianguo Li
Jianguo Li
ZLZhiyong Liu
Zhiyong Liu
YWYunbing Wang
Yunbing Wang

14 April 2023 in Science Advances
Verified
Journal Article
Open access
YJYu Jiang
Yu Jiang
JYJinlong Yang
Jinlong Yang
RLRuichao Liang
Ruichao Liang
XZXin Zan
Xin Zan
RFRangrang Fan
Rangrang Fan
JXJianguo Xu
Jianguo Xu
Despite improvements in microscopically neurosurgical techniques made in recent years, the prognosis of adamantinomatous craniopharyngioma (ACP) is still unsatisfactory. Little is known about cellular atlas and biological features of ACP. Here, we carried out integrative analysis of 44,038 single-cell transcriptome profiles to characterize the landscape of intratumoral heterogeneity and tumor microenvironment (TME) in ACP. Four major neoplastic cell states with distinctive expression signatures were defined, which further revealed the histopathological features and elucidated unknown cellular atlas of ACP. Pseudotime analyses suggested potential evolutionary trajectories between specific neoplastic cell states. Notably, a distinct oligodendrocyte lineage was identified in ACP, which was associated with immunological infiltration and neural damage. In addition, we described a tumor-centric regulatory network based on intercellular communication in TME. Together, our findings represent a unique resource for deciphering tumor heterogeneity of ACP, which will improve clinical diagnosis and treatment strategies.

12 September 2022 in Materials Today Bio
Verified
Journal Article
Open access
YHYihong He
Yihong He
XZXin Zan
Xin Zan
JMJunming Miao
Junming Miao
BWBilan Wang
Bilan Wang
YWYin Wu
Yin Wu
XGXiang Gao
Xiang Gao
Current treatment of glioma is hampered due to the physical blood-brain barrier (BBB) and the resistance to traditional chemotherapeutic agents. Herein, we proposed a combined treatment strategy based on Cyclo (Arg-Gly-Asp-d-Phe-Lys) (cRGDfk) peptides-modified nanoparticle named cRGD-P in a self-assembly method for the co-delivery of doxorubicin (DOX) and BRD4 PROTAC degrader ARV-825 (ARV). Molecular dynamics simulations showed that cRGD-P could change its conformation to provide interaction sites for perfectly co-loading DOX and ARV. The cRGD-P/ARV-DOX exhibited an average size of 39.95 ​nm and a zeta potential of −0.25 ​mV. Increased expression of BRD4 in glioma cells was observed after being stimulated by cRGD-P/DOX, confirming one of the possible mechanisms of DOX resistance and the synergistic tumor inhibition effect of BRD4 degrading ARV combined with DOX. In the study, the combination of DOX and ARV in the cRGD-P nanoparticle system exhibited synergistic suppression of tumor growth in glioma cells on account of cell cycle arrest in the G2/M phase and the activation of tumor cells apoptosis-related pathways including triggering caspase cascade and downregulating Bcl-2 as well as upregulating Bax. The cRGD-P/ARV-DOX system could effectively suppress the heterotopic and orthotopic growth of glioma by increasing tumor apoptosis, inhibiting tumor proliferation, and decreasing tumor angiogenesis in vivo. Therefore, the cRGD-modified nanoparticle to co-deliver DOX and ARV provides a potential platform for exploiting a more effective and safer combination therapy for glioma.

1 September 2021 in Epilepsy Research
Verified
Journal Article
Closed access
XZXin Zan
Xin Zan
GYGaohui Yue
Gaohui Yue
YHYongli Hao
Yongli Hao
XSXiutian Sima
Xiutian Sima

14 June 2022 in Chinese Chemical Letters
Verified
Journal Article
Closed access
ZHZehua Hong
Zehua Hong
XZXin Zan
Xin Zan
TYTing Yu
Ting Yu
YHYuzhu Hu
Yuzhu Hu
HGHongfeng Gou
Hongfeng Gou
PZPeizhi Zhou
Peizhi Zhou

14 December 2021 in Frontiers in Surgery
Verified
Journal Article
Open access
JLJiuhong Li
Jiuhong Li
XZXin Zan
Xin Zan
MFMin Feng
Min Feng
XDXueyun Deng
Xueyun Deng
SZSi Zhang
Si Zhang
WLWenke Liu
Wenke Liu
Lymphoplasmacyte-rich meningioma (LRM) is a rare histologic subtype of meningioma. Creeping-growth pattern is uncommon in meningioma, and the mechanism is unclear. Here, we report a 44-year-old man presented with extremities weakness for 2 months and incontinence for 2 weeks. Head and neck MRI revealed diffuse creeping-growth nodular meningeal masses with skull base, tentorium, sella area, and C1-6 vertebral plane involvement. An operation was carried out, cervical and lower clivus part of the lesion was resected, but gross total resection could not be achieved due to the widespread lesions. Pathologic examination revealed the diagnosis of LRM. The patient is free from progression clinically 3 months postoperatively. We also conducted a systematic literature review about LRM with creeping-growth pattern. A total of only nine cases (including the present case) of creeping-growth LRMs were included and analyzed in terms of clinical manifestations, radiological features, treatment, and outcome. LRMs show a higher rate (7.5%) of creeping-growth pattern than other types of meningiomas. The average creeping length of all creeping-growth LRMs was 11.4 ± 10.9 cm (range, 3–30 cm). Most cases (66.7%) had obvious peritumoral edema. Total removal rate is low (33.3%), and two of them (22.2%) received biopsy, followed by steroids treatment (or further immunosuppressive drugs therapy) and radiotherapy. The recurrence rate is higher than conventional LRMs (22.2 vs. 11.3%), and one patient (11.1%) died 11 months after treatment. Creeping-growth pattern in LRM may be considered as a general radiologic variant. The recurrence rate is higher compared with LRM with round/swelling pattern. We speculated that the pathogenesis of creeping growth in LRM may be associated with damage of lymphatic systems of the central nervous system.